AD HAFT Peak Pruritus NRS Efficacy Results

12+ YEARS

Itch reduction results at Week 16 (secondary endpoint)

Improvement after first dose at Week 2
(15% vs 3%)

Percentage of patients achieving ≥4-point
reductionin hand and foot Peak Pruritus NRS

Weeks

52%

≈4x as many
patients
(P<0.0001)

14%

DUPIXENT 200/300 mg Q2W (n=67) Placebo (n=66)

Definitive conclusions cannot be made for time points earlier than Week 16 as those data were not multiplicity-controlled
and P value was nominal.

Not an actual patient.

≈4x

As many patients

taking DUPIXENT achieved itch improvement at Week 16 vs placebo^1,2

taking DUPIXENT achieved itch
improvement at Week 16 vs placebo^1,2

Dosage and
administration

Thinking about prescribing DUPIXENT? Find the information you need to get started.